A landmark Indian study of more than 9,000 adults has quietly redrawn the map of diabetes complications, revealing that the liver — long absent from the standard conversation — is silently scarring in one of every four people living with Type 2 Diabetes. The DiaFib-Liver Study places advanced liver disease alongside the eye, kidney, and nerve damage that clinicians have long monitored, suggesting that millions may be managing one illness while unknowingly harboring another. In a country carrying one of the world's heaviest burdens of diabetes, the findings ask a pointed question about what rou
Indian study reveals liver fibrosis as 'fourth major complication' of Type 2 diabetes
Millions of Indian diabetics face silent liver damage risk with potential progression to cirrhosis and liver failure if undetected and unmanaged.
The liver is quietly accumulating damage in a quarter of all diabetics
Mark
So this study is saying one in four diabetics in India have significant liver scarring. That's a huge number. Why hasn't this been caught before?
Mimi
The liver doesn't announce itself. You can have fibrosis building for years without any symptoms. Doctors have been focused on the classic diabetes complications—heart, kidney, eye damage—because those are what we've always measured. The liver was just assumed to be fine.
Luke
But we should be careful here. The study looked at over 9,000 people, which is solid. But I want to know: were these people representative of all Indian diabetics, or were they selected in some way? And the fibrosis detection—that's based on elastography thresholds. Those thresholds are standardized, but they're not perfect.
Mimi
Fair point. The study does establish that fibrosis is common and serious. But you're right that we need to know the methodology to understand if this 25 percent figure applies equally to all diabetics or if certain groups are at higher risk.
Mark
What's the difference between having fat in your liver and having scarring? They sound like they're on the same spectrum.
Mimi
They are on a spectrum, but they're not the same thing. Fat can go away if you lose weight and control your blood sugar. Scarring doesn't. Once fibrosis develops, it's permanent. That's why the doctors in the story are saying we need to screen for fibrosis specifically, not just assume fatty liver is harmless.
Luke
The study recommends FibroScan screening for diabetics. But FibroScan isn't available everywhere in India, and it costs money. So the practical question is: how do we actually implement this recommendation in a country with 100 million diabetics?
Mimi
That's the real challenge. The science is clear—fibrosis matters, screening matters. But translating that into clinical practice, especially in resource-limited settings, is a different problem.
Mark
If someone has fibrosis, can anything be done about it?
Mimi
The sources I have focus on prevention and early detection. Lifestyle changes—weight loss, exercise, diet—can slow progression. But once scarring has happened, reversing it is much harder. That's why early detection is so critical.
Luke
And we should note: the study doesn't tell us what percentage of people with fibrosis will actually progress to cirrhosis or liver failure. One in twenty has probable cirrhosis, but what about the one in four with fibrosis? How many of them will get worse?
Mimi
That's an important gap. The study establishes the prevalence, but the natural history—how fast it progresses, who's at highest risk of complications—that's still being worked out.
El Pulso
- One in four Indian adults with Type 2 Diabetes has clinically significant liver fibrosis — irreversible scarring — and one in twenty has already reached probable cirrhosis, yet most patients feel nothing at all.
- The danger is its silence: liver damage can advance for years without symptoms, and by the time fatigue, jaundice, or swelling appear, the window for reversal may already be closed.
- Insulin resistance drives fat deep into liver tissue, and over time that fat ignites chronic inflammation that transforms healthy cells into scar tissue — a process distinct from, and far more serious than, ordinary fatty liver.
- Current clinical practice focuses heavily on blood sugar, leaving the liver largely unmonitored in diabetic care — a gap this study is now pressing doctors to close.
- Experts are calling for systematic FibroScan screening and targeted lifestyle changes — weight control, reduced refined carbohydrates, regular exercise — as the practical path to catching fibrosis before it becomes irreversible.
A landmark Indian study of more than 9,000 adults has quietly redrawn the map of diabetes complications, revealing that the liver — long absent from the standard conversation — is silently scarring in one of every four people living with Type 2 Diabetes. The DiaFib-Liver Study places advanced liver disease alongside the eye, kidney, and nerve damage that clinicians have long monitored, suggesting that millions may be managing one illness while unknowingly harboring another. In a country carrying one of the world's heaviest burdens of diabetes, the findings ask a pointed question about what routine care has been missing — and what the cost of that omission may be.
When diabetes complications are discussed, the conversation reliably lands on the heart, kidneys, and eyes. A major Indian study published in 2026 is asking why the liver is so rarely part of that conversation.
The DiaFib-Liver Study examined more than 9,000 adults across multiple centres and found that one in four Indian patients with Type 2 Diabetes has clinically significant liver fibrosis — scarring of liver tissue — and one in twenty has already progressed to probable cirrhosis. The researchers describe advanced liver disease as a 'fourth major complication' of diabetes, one that has long been overshadowed by the microvascular conditions dominating clinical attention.
The underlying condition is MASLD — metabolic dysfunction-associated steatotic liver disease — which begins when excess fat accumulates in the liver due to obesity and insulin resistance. Up to 70 percent of diabetics carry fat in their livers. The critical distinction, specialists emphasise, is between steatosis and fibrosis: fat accumulation is largely reversible if caught early, but scar tissue is not. Fibrosis is the true marker of disease severity and the predictor of outcomes including liver failure and death.
What makes this particularly dangerous is silence. Liver damage can progress for years without any symptoms. By the time a patient notices fatigue, jaundice, or abdominal swelling, the disease may already be difficult to reverse. Standard clinical focus on blood sugar control, while necessary, leaves the liver unmonitored.
Experts recommend a two-track response: lifestyle changes — weight management, reduced refined carbohydrates, regular exercise, controlled blood sugar and cholesterol — combined with systematic screening through liver enzyme tests and FibroScan, a non-invasive technique that detects fibrosis before it becomes cirrhosis. For millions of Indian diabetics, the study suggests that preventing liver failure may depend on whether clinical practice expands its gaze beyond the measures it has long relied upon.
When people think about diabetes complications, the conversation usually turns to the heart, the kidneys, the eyes. A large Indian study released in 2026 is asking why the liver barely gets a mention. The DiaFib-Liver Study, a multicentre investigation, examined over 9,000 adults and found something that challenges the standard way diabetes is discussed in clinical practice: the liver is quietly accumulating damage in a quarter of all Indian patients with Type 2 Diabetes, and most of them have no idea it's happening.
The condition at the center of this finding is called Metabolic dysfunction-associated steatotic liver disease, or MASLD—a newer name for what was previously known as fatty liver disease. It begins simply enough: excess fat builds up in the liver because of metabolic problems like obesity and insulin resistance. But the study's real concern is not the fat itself. It is what comes after. The researchers found that one in four adults with Type 2 Diabetes in India has clinically significant liver fibrosis—scarring of the liver tissue. One in twenty has already progressed to probable cirrhosis. These numbers establish advanced liver disease as what the researchers call a "fourth major complication" of diabetes, sitting alongside the microvascular complications—retinopathy, nephropathy, and neuropathy—that have long dominated the conversation.
Dr. Kapil Sharma, Group Director of Gastroenterology at Yatharth Super Speciality Hospital in Faridabad, explains the mechanism. When someone has insulin-resistant Type 2 Diabetes, the body stores both fat and glucose abnormally. Fat accumulates not just under the skin but inside the liver itself. According to available statistics, up to 70 percent of all diabetics have fat stored in their livers. Over time, this fat triggers inflammation and sets off multiple pathways of damage—chronic inflammatory responses, abnormal lipid metabolism—that gradually transform healthy liver tissue into scar tissue.
The distinction between steatosis and fibrosis matters enormously, Sharma emphasizes. Steatosis is the accumulation of fat in the liver, and it is largely reversible if caught early. It may cause no immediate harm. Fibrosis, by contrast, represents the creation of scar tissue from ongoing damage and inflammation. Unlike fat, scar tissue does not go away. Fibrosis signals that the disease is progressing toward something far more serious. It is strongly associated with cirrhosis, liver failure, and increased risk of death. This is why experts now argue that screening should focus on detecting fibrosis, not just steatosis—fibrosis is the true marker of disease severity and the predictor of long-term outcomes.
The danger lies in silence. Liver damage can remain undetected for years. By the time a patient develops symptoms—fatigue, jaundice, abdominal swelling—the disease may already be advanced and difficult to reverse. For people with diabetes, this means the standard clinical focus on blood sugar control, while necessary, is not enough. The liver needs attention too.
Management begins with lifestyle. Patients should control their weight, eat a balanced diet, and exercise regularly to reduce fat accumulation in the liver. Refined carbohydrates and alcohol should be minimized. Blood sugar levels should be kept as low as possible. Cholesterol and blood pressure need management. But lifestyle alone is not sufficient. The researchers recommend systematic screening: regular liver enzyme testing and FibroScan, a non-invasive ultrasound-based technique that measures liver stiffness and can detect fibrosis before it becomes cirrhosis. Early detection allows intervention before irreversible damage takes hold.
For millions of Indian diabetics, this study suggests a hidden risk that has been overlooked in routine care. The question now is whether clinical practice will shift to match what the evidence shows—that looking beyond blood sugar and paying systematic attention to liver health could prevent progression to liver failure and death.
Citas Notables
Fibrosis indicates that the disease is progressing toward something far more serious and is strongly associated with cirrhosis, liver failure, and increased risk of death.— Dr. Kapil Sharma, Group Director of Gastroenterology, Yatharth Super Speciality Hospital
Screening should focus on detecting fibrosis, not just steatosis, because fibrosis is the true marker of disease severity and predictor of long-term outcomes.— Dr. Kapil Sharma
Quieres la nota completa?
Lee el original en Times of India ↗
Health & Medicine